NEW
Molnupac 200/Molnupac 400

Molnupac 200/Molnupac 400

molnupiravir

Manufacturer:

Pacific Medical

Distributor:

AA Medical
Concise Prescribing Info
Contents
Molnupiravir
Indications/Uses
Mild to moderate COVID-19 in adults w/ +ve SARS-CoV-2 & who have at least 1 risk factor for developing severe illness.
Dosage/Direction for Use
800 mg every 12 hr for 5 days, taken as soon as possible after diagnosis of COVID-19 & w/in 5 days of symptom onset.
Special Precautions
Administration for >5 days has not been established. Women of childbearing potential should use effective contraception during treatment & for 4 days after last dose. Not recommended during pregnancy. Breastfeeding is not recommended during treatment & for 4 days after last dose. Childn <18 yr.
Adverse Reactions
MIMS Class
Antivirals
ATC Classification
J05 - ANTIVIRALS FOR SYSTEMIC USE ; Used in the systemic treatment of viral infections.
J05AB - Nucleosides and nucleotides excl. reverse transcriptase inhibitors ; Used in the systemic treatment of viral infections.
Presentation/Packing
Form
Molnupac 200 hard cap 200 mg
Packing/Price
1 × 40's;4 × 10's
Form
Molnupac 400 hard cap 400 mg
Packing/Price
2 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in